Comparison of Quadriceps and Semitendinosus Grafts in ACL Reconstruction Using Data From the Danish Knee Ligament Reconstruction Registry (DKRR)
Launched by ABDIRAHMAN HASSAN OMAR · May 12, 2025
Trial Information
Current as of July 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating two different types of tissue used in surgery to repair a torn anterior cruciate ligament (ACL) in the knee, a common injury among active individuals. The study compares grafts taken from the quadriceps muscle at the front of the thigh and the semitendinosus muscle at the back. Researchers will analyze data from a national health registry to see how well patients recover after surgery, focusing on their knee function, activity levels, and whether they need any additional surgeries.
To participate in this study, you should be between the ages of 15 and 50 and have had a primary ACL reconstruction using either the quadriceps or semitendinosus graft. You also need to have been followed up for at least one year after your surgery with completed questionnaires about your knee health and activity. The trial is not currently recruiting participants, but if you meet these criteria, you may be eligible once it begins. This research aims to help improve recovery outcomes for patients who undergo ACL reconstruction.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Primary ACL reconstruction registered in the Danish Knee Ligament Reconstruction Registry (DKRR)
- • Known graft type: quadriceps tendon or semitendinosus tendon Minimum 1-year follow-up with completed patient-reported outcome measures (KOOS and/or Tegner score)
- • Age between 15 and 50 years at the time of surgery (optional subgroup analysis)
- Exclusion Criteria:
- • Revision ACL reconstruction
- • Multiligament knee reconstruction
- • Missing or incomplete PROMs or key clinical data
About Abdirahman Hassan Omar
Abdirahman Hassan Omar is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a strong focus on innovative therapies and treatments, he collaborates with leading research institutions and healthcare professionals to design and execute rigorous clinical trials. His expertise in regulatory compliance, patient safety, and data integrity ensures that all studies adhere to the highest ethical standards. Through his leadership, Abdirahman aims to contribute significantly to the development of effective healthcare solutions that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, Frederiksberg, Denmark
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported